Literature DB >> 16945046

Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.

Amber L Beitelshees1, Issam Zineh, Hossein N Yarandi, Daniel F Pauly, Julie A Johnson.   

Abstract

STUDY
OBJECTIVES: To determine the correlation between ambulatory and clinic blood pressure in assessing antihypertensive response to beta-blockade, to test whether blood pressure response to metoprolol is associated with the heart rate response, and to determine whether exercise and resting heart rate responses to metoprolol are correlated.
DESIGN: Post hoc analysis of a prospective cohort study.
SETTING: University-affiliated general clinical research center. PATIENTS: Fifty-one patients aged 35-65 years with uncomplicated hypertension. Intervention. All patients received metoprolol at a dosage titrated to achieve a diastolic blood pressure below 90 mm Hg.
MEASUREMENTS AND MAIN RESULTS: Clinic and 24-hour ambulatory blood pressure measurements were obtained and exercise treadmill testing was performed before and after metoprolol treatment. Based on ambulatory blood pressure data, 24 patients (47%) responded (defined as at least a 10% reduction in diastolic blood pressure) to metoprolol compared with 36 patients (71%) based on clinic blood pressure data (p=0.027). Clinic blood pressure was associated with a 67% false-positive rate (responsive blood pressure by clinic data that was actually nonresponsive by ambulatory data). Blood pressure responders and nonresponders exhibited similar reductions in exercise heart rate (24% and 23%, p=0.74). However, responses to metoprolol measured by exercise heart rate versus resting heart rate were not significantly correlated (r=0.24, p=0.105).
CONCLUSION: Reliance on clinic blood pressure or resting heart rate for making beta-blocker treatment decisions may yield less than optimal assessment of the antihypertensive response or degree of beta-blockade.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945046     DOI: 10.1592/phco.26.9.1247

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

Review 1.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

2.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

3.  Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.

Authors:  Amber L Beitelshees; Yan Gong; Kent R Bailey; Stephen T Turner; Arlene B Chapman; Gary L Schwartz; John G Gums; Eric Boerwinkle; Julie A Johnson
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-01       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.